AevisBio entered into a collaborative research with NCI
관리자 │ 2023-01-17
AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases, has entered into a collaborative research with the National Cancer Institute, an institute of the National Institutes of Health (NIH), U.S. Department of Health and Human Services since January 2021. This collaboration is for the development of NIH-developed anti-inflammatory drug candidates for the management of acute and chronic neurological disorders.
|Previous Post||Patent license agreement with NIH|
|Next Post||Chemical Research Center founded at Institut Pasteur Korea, Pan-gyo, Korea|